Metfogamma

Metformin, the active ingredient in Metfogamma, is a biguanide presented as an oral tablet for oral administration. It is used to improve glycemic control in adults with type 2 diabetes mellitus, helping to lower elevated blood glucose levels.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The product complies with European Union pharmacopeial standards and undergoes rigorous quality testing before distribution, ensuring consistent potency and safety.

Metfogamma (metformin) is used in the management of disorders related to impaired glucose metabolism. - Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): may delay progression to overt diabetes. - Polycystic ovary syndrome: can improve insulin resistance and help regulate menstrual cycles.

Metfogamma may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: persistent metallic sensation in the mouth. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight. Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term use. - Hepatic dysfunction: abnormal liver enzymes. - Skin rash: including severe reactions such as Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas.

Metfogamma requires careful monitoring to ensure safe use. - Renal function assessment: evaluate kidney function before initiation and periodically thereafter. - Hepatic function monitoring: check liver enzymes in patients with liver disease. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Concomitant medication review: assess for drugs that may increase metformin levels. - Dose adjustment in elderly: consider lower starting doses for older adults. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metfogamma can interact with several medicines, altering its efficacy or safety. Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before imaging. - Cimetidine: can increase metformin plasma concentrations. - Excessive alcohol intake: heightens risk of lactic acidosis. Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: may enhance risk of hypoglycemia. - Beta‑blockers: can mask hypoglycemia symptoms. - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Warfarin: may alter INR, necessitating closer monitoring.